教育・研究
業績 業績
Performance

業績

2021年

論文発表

  1. Enokiya T, Nishikawa K, Hamada Y, Ikemura K, Sugimura Y, Okuda M,
    Temporary decrease in tacrolimus clearance in cytochrome P450 3A5
    non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene. Basic Clin Pharmacol Toxicol, 128(3): 525-533 (2021)
  2. Okamoto A, Ikemura K, Mizutani E, Iwamoto T, Okuda M., Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study. J Pharm Health Care Sci. 7(1): 3 (2021). doi: 10.1186/s40780-020-00187-3.
  3. 村地康、細川祐岐、衣笠裕香、山本智也、奥田真弘、抗がん剤の実地調製における曝露対策としてのネオシールド®の有用性評価、日本病院薬剤師会雑誌57(1): 63-69 (2021).
  4. 中村洋平、⼩倉裕司、松井浩子、前田真一郎、嶋津岳士、持続血液濾過透析により改善したメトホルミンによる乳酸アシドーシスの1例. 日本救急医学会雑誌、32:86-91 (2021).
2020年

論文発表

  1. Ogami C, Tsuji Y, Muraki Y, Mizoguchi A, Okuda M, To H, Population pharmacokinetics and pharmacodynamics of teicoplanin and C-reactive protein in hospitalized patients with gram-positive infections. Clin Pharmacol Drug Dev. 9: 175-188 (2020). doi: 10.1002/cpdd.684.
  2. Enokiya T, Hasegawa M, Muraki Y, Morikawa Y, Iwamoto T, Sudo A, Okuda M, Postoperative anaemia is a risk factor for major bleeding in thromboprophylaxis using fondaparinux sodium injection after total knee or hip arthroplasty. Biol Pharm Bull, 43: 266-271 (2020).
  3. Urano K, Ishibashi M, Matsumoto T, Ohishi K, Muraki Y, Iwamoto T, Kunimasa J, Okuda M, Impact of physician−pharmacist collaborative protocol-based pharmacotherapy management for HIV outpatients: a retrospective cohort study. J Pharm Health Care Sci, 6: 9 (2020).
  4. Hiramatsu S, Ikemura K, Fujisawa Y, Iwamoto T, Okuda M, Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats. Biopharm Drug Dispos, 41(6): 239-247 (2020).
  5. Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, Iwamoto K, Kishimoto T, Horai T, Yamada H, Sugiyama N, Nakamura T, Tsujino N, Nemoto K, Oishi S, Usami M, Katsumoto E, Yamamori H, Tomita H, Suwa T, Furihata R, Inagaki T, Fujita J, Onitsuka T, Miura K, Matsumoto J, Ohi K, Matsui Y, Takaesu Y, Hashimoto N, Iga J, Ogasawara K, Yamada H, Watanabe K, Inada K, Hashimoto R. Prescription patterns in patients with schizophrenia in Japan: first-quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project. Neuropsychopharmacol Rep, 40(3):281-286, (2020). DOI:10.1002/npr2.12122
  6. Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, Matsumoto J, Murata A, Ogasawara K, Yamada H, Hori H, Ichihashi K, Hashimoto N, Ohi K, Yasui-Furukori N, Tsuboi T, Nakamura T, Usami M, Furihata R, Takaesu Y, Iwamoto K, Sugiyama N, Kishimoto T, Tsujino N, Yamada H, Hishimoto A, Nemoto K, Atake K, Muraoka H, Katsumoto E, Oishi S, Inagaki T, Ito F, Imamura Y, Kido M, Nagasawa T, Numata S, Ochi S, Iwata M, Yamamori H, Fujita J, Onitsuka T, Yamamura S, Makinodan M, Fujimoto M, Takayanagi Y, Takezawa K, Komatsu H, Fukumoto K, Tamai S, Yamagata H, Kubota C, Horai T, Inada K, Watanabe K, Kawasaki H, *Hashimoto R. Unmet need for major depressive disorders-Findings from the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci,74(12):667-669 (2020). DOI:10.1111/pcn. 13143
  7. Wakai E, Suzumura Y, Ikemura K, Mizuno T, Watanabe M, Takeuchi K, Nishimura Y, An Integrated in silico and in vivo approach to identify protective effects of palonosetron in cisplatin-induced nephrotoxicity. Pharmaceuticals. 13(12): 480 (2020). DOI.org/10.3390/ph13120480
  8. Mizutani H, Shiga C, Imai M, Ikemura K, Kitamura Y, Ohta K, Miyazawa D, Sakanashi M, Tahira T, Maeda T, Hiraku Y, Kawanishi S, Idarubicin, an anthracycline, induces oxidative DNA damage in the presence of copper (II). Anticancer Res. 40(10): 5399-5404 (2020) DOI: 10.21873/anticanres.14548
  9. 若井恵里,池村健治,山崎大輔,石原幹也,岩本卓也,奥田真弘,高速液体クロマトグラフィー(HPLC)を用いた簡便な血清中ミトタン濃度測定法の開発と臨床応用. TDM研究37 (2): 77-83 (2020).
  10. 松井浩子,竹川良介,大西光雄,門脇裕子,嶋津岳士,アシクロビル脳症の1例―腎機能障害下でのアシクロビル投与に関する考察―.中毒研究33(3): 216-218 (2020).
2019年

受賞

  1. 新谷 拓也 日本医療薬学会Postdoctral Award
    新規EGFR-TKI耐性獲得因子eIF3cの分子病理学的意義の解明とバイオマーカーとしての有用性の検討

論文発表

  1. Kitayama K, Maeda S, Nakamura A, Katayama I, Wataya-Kaneda M, Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation. J Dermatol Sci. 94: 350-353 (2019).
  2. Nakagami H, Sugimoto K, Ishikawa T, Koshizaka M, Fujimoto T, Kiyohara E, Hayashi M, Nakagawa Y, Ando H, Terabe Y, Takami Y, Yamamoto K, Takeya Y, Takemoto M, Ebihara T, Nakamura A, Nishikawa M, Xiang Jing Yao, Hanaoka H, Yokote K, Rakugi H, Investigator-initiated clinical study of a functional peptide, SR-0379, for limb ulcers of patients with Werner syndrome as a pilot study. Geriatr Gerontol Int. 19(11):1118-1123 (2019).
  3. Ju N, Shimamura M, Hayashi H, Ikeda Y, Yoshida S, Nakamura A, Morishita R, Rakugi H, Nakagami H. Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimodinduced psoriasis. Sci Rep. 9(1): 15434 (2019).
  4. Kokado R, Hagiya H, Morii D, Okuno H, Yamamoto N, Hamaguchi S, Yoshida H, Miwa Y, Tomono K. Broad-spectrum antibiotic prescriptions are discontinued unevenly throughout the week. J Hosp Infect. 101(4):471-474 (2019).
  5. Kokado R, Hagiya H, Koyama T, Matsui E, Okuno H, Morii D, Hamaguchi S, Yoshida H, Miwa Y, Tomono K. Antibiotic-associated adverse drug events at a Japanese academic hospital. J Infect Chemother. 25(5):392-395 (2019).
  6. Hagiya H, Kokado R, Okuno H, Tomono K. Daptomycin-associated myopathy induced by concomitant administration of mirabegron. Infection. 47(2): 331-332 (2019).
  7. Morii D, Kokado R, Tomono K. Hospital-by-hospital carbapenem use in Japan: a nationwide ecological study. J Hosp Infect. 102(1):101-107 (2019).
  8. Hagiya H, Kokado R, Ueda A, Okuno H, Morii D, Hamaguchi S, Yamamoto N, Yoshida H, Tomono K. Association of Adverse Drug Events with Broad-spectrum Antibiotic Use in Hospitalized Patients: A Single-centered Study. Intern Med. 58(18):2621-2625 (2019).
  9. Ikemura K, Hiramatsu S, Shinogi Y, Nakatani Y, Tawara I, Iwamoto T, Katayama N, Okuda M. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. Sci Rep. 9(1):20359 (2019).
  10. Matsuura H, Ujiie K, Duyen TTM, Izutsu K, Fujiyama K, Maeda S, et al. Development of a Paper-Based Luminescence Bioassay for Therapeutic Monitoring of Aminoglycosides: a Proof-of-Concept Study. Applied Biochemistry and Biotechnology. 189(3):798-809 (2019).
  11. Sasano M, Ohno M, Fukuda Y, Nonen S, Hirobe S, Maeda S, Miwa Y, Yokoyama J, Nakayama H, Miyagawa S, Sawa Y, Fujio Y, Maeda M. Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients. Eur J Clin Pharmacol. 75(7):901-911 (2019).
  12. 浦嶋庸子、岩本瑞樹、池田賢二、米田勇太、井上麻衣、松本数博、山崎肇、西川満則、廣谷芳彦. 院内製剤フェノールグリセリン注射剤の安定性評価.日本病院薬剤師会雑誌、55(10):1191-1194 (2019).
ページ上部へ